Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TELA Bio, Inc. - Common stock (NQ:TELA)

1.995 -0.045 (-2.21%)
Streaming Delayed Price Updated: 2:16 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TELA Bio, Inc. - Common stock

< Previous 1 2 3 4 5 Next >
Deep Dive Into TELA Bio Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
TELA Bio Reports Third Quarter 2024 Financial Results
Reiterates 2024 Revenue Guidance and Expects Recently Implemented Operational Efficiency Improvements to Reduce Operating Expenses in 2025 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From TELA Bio, Inc.
Via GlobeNewswire
Demystifying TELA Bio: Insights From 6 Analyst Reviews
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From TELA Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Recap: TELA Bio Q4 Earnings
Via Benzinga
TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce Third Quarter 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results
Via Benzinga
S&P 500 Gains 1%; Home Depot Earnings Top Views
Via Benzinga
Topics Stocks
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
Via Benzinga
TELA Stock Earnings: TELA Bio Misses EPS, Misses Revenue for Q2 2024
TELA stock results show that TELA Bio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Conference
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce Second Quarter 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Appoints Jeffrey Blizard to its Board of Directors
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Appoints Greg Firestone as Chief Commercial Officer
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q1 2024
TELA stock results show that TELA Bio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
TELA Bio Reports First Quarter 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce First Quarter 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.) 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023
TELA stock results show that TELA Bio missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue 
From TELA Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.